Genvor INC

Genvor Incorporated announced the appointment of Donald Kalkofen as its new Chief Financial Officer, effective May 18, 2026, bringing extensive experience in public company finance and capital markets.

Genvor Incorporated has designated four shares of Series C Preferred Stock and issued one share to Brio Advisory Group LLC as part of an advisory agreement.

Genvor Incorporated has entered into a securities purchase agreement for up to $800,000 in convertible notes and warrants, alongside an advisory agreement with Brio Advisory Group.

Genvor Incorporated announced the addition of its updated September 2025 investor presentation to its company website.

Genvor Incorporated files its Q2 2026 Form 10-Q, detailing increased R&D spending, significant stock-based compensation adjustments, and a new financing agreement.

Genvor Incorporated filed an amendment to its Q1 2026 quarterly report to correct typographical errors and update certifications, while reiterating significant financial challenges including a going concern warning.

Genvor Incorporated reported a significantly reduced net loss in Q1 2026, driven by lower operating expenses, while continuing to develop its AI-accelerated peptide technology despite ongoing liquidity concerns.

Genvor Incorporated reported a significant increase in net loss for the nine months ended June 30, 2025, raising substantial doubt about its ability to continue as a going concern despite R&D advancements and a Bayer partnership.

Genvor Incorporated reported a significant net loss for the six months ended March 31, 2025, and faces substantial doubt about its ability to continue as a going concern, despite recent capital raises and technological advancements.

Genvor Incorporated, a pioneer in AI-accelerated peptide technology for sustainable agriculture, reported a significant net loss for fiscal year 2025 while advancing its proprietary BioCypher Algorithm and securing a Bayer Golden Ticket award.

Genvor Incorporated filed an amended annual report to correct an audit opinion date, reiterating significant financial challenges and a going concern warning.

CEO Chad Pawlak acquired 250,000 shares of Genvor Inc. through the conversion of $125,000 in outstanding company payables.

Genvor Inc. reports that CEO Chad Pawlak acquired 250,000 shares of common stock as part of a restructured compensation package.

Genvor Inc.'s CEO, Chad Lee Pawlak Sr., acquired 250,000 shares of common stock as a compensation award, increasing his direct beneficial ownership to 6,500,000 shares.

Genvor Inc.'s Chief Research Officer, Jessee M. Jaynes, converted $286,000 in accrued payables into 524,000 shares of common stock across two transactions.

Genvor Inc.'s CEO, Director, and 10% owner, Chad Lee Pawlak Sr., acquired 250,000 shares of common stock as a compensation award, increasing his direct beneficial ownership to 6,250,000 shares.